Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, PRTK is expected to report 3Q20 loss of $ 0.61 per share from revenue of $ 11.90 million.
For the full year, analysts anticipate top line of $ 82.05 million, while looking forward to loss of $ 1.77 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 78.00 million ~ $ 83.00 million
Click Here For More Historical Outlooks Of Paratek Pharmaceuticals, Inc.
Previous Quarter Performance
Paratek Pharmaceuticals, Inc. posted loss for the second quarter of $ 0.53 per share, from the revenue of $ 9.33 million. The quarterly revenues developed 398.93 percent compared with the same quarter last year. Street analysts expected Paratek Pharmaceuticals, Inc. to report loss of $ 0.06 per share on revenue of $ 38.03 million for the second quarter. The top line results fell short of analysts by $ 28.7 million or 75.47 percent.
Stock Performance
Shares of Paratek Pharmaceuticals, Inc. traded up $ 0.27 or 5.79 percent on Wednesday, reaching $ 4.93 with volume of 181.70 thousand shares. Paratek Pharmaceuticals, Inc. has traded high as $ 4.95 and has cracked $ 4.66 on the downward trend
The closing price of $ 4.93, representing a 86.40 % increase from the 52 week low of $ 2.50 and a 30.65 % decrease over the 52 week high of $ 6.72.
The company has a market capital of $ 234.44 million and is part of the Healthcare sector and Biotechnology industry.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd.
